Shopping Cart
- Remove All
Your shopping cart is currently empty
Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen, addressing the mechanisms of Pompe disease. It combines the Fab segment of a cell-penetrating antibody with recombinant human acid alpha-glucosidase (rhGAA). The Fab portion utilizes the nucleoside transporter ENT-2 for cytosolic entry, while rhGAA accesses lysosomes via mannose-6-phosphate receptors (M6PRs). This dual-targeting approach suggests Clervonafusp alfa as a potential therapeutic research candidate for late-onset Pompe disease [1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | Inquiry | Backorder | |
| 50 mg | Inquiry | Backorder |
| Description | Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen, addressing the mechanisms of Pompe disease. It combines the Fab segment of a cell-penetrating antibody with recombinant human acid alpha-glucosidase (rhGAA). The Fab portion utilizes the nucleoside transporter ENT-2 for cytosolic entry, while rhGAA accesses lysosomes via mannose-6-phosphate receptors (M6PRs). This dual-targeting approach suggests Clervonafusp alfa as a potential therapeutic research candidate for late-onset Pompe disease [1]. |
| Cas No. | 2145123-44-8 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.